61It should be added that it is only at the authorisation stage of a biocidal product, with a view to placing it on the market, that all the intended uses of that product and its efficacy on all of the target organisms will be examined in detail and an assessment of the product’s efficacy and risks, having regard to each of those uses, will be carried out. Such an in-depth assessment is not required at the approval stage of an active substance, as stated in the ECHA guidance document referred to in paragraph 60 above. The efficacy assessment of an active substance is therefore in actual fact more limited than that of a biocidal product in the context of a marketing authorisation procedure.